Thromboembolic events and cardiovascular disease are the most prevalent complications in
patients with polycythemia vera (PV) compared with other myeloproliferative disorders and …

Polycythemia vera (PV) is mainly characterized by elevated blood cell counts, thrombotic as
well as hemorrhagic predisposition, a variety of symptoms, and cumulative risks of fibrotic …

Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK) 1 and JAK2
inhibitor, was superior to best available therapy at controlling haematocrit and improving …

Background Polycythaemia vera is a myeloproliferative neoplasm characterised by
excessive proliferation of erythroid, myeloid, and megakaryocytic components in the bone …

We conducted a large international nested case-control study including 1881 patients with
Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n= 647) were patients …

The past five decades have seen an improvement in the mortality and morbidity of sickle cell
disease (SCD) because of prophylaxis against infectious complications, improved and …

Essential thrombocythemia (ET) is an indolent myeloproliferative neoplasm that may be
complicated by vascular events, including both thrombosis and bleeding. This disorder may …

Polycythemia vera (PV) is a chronic myeloproliferative neoplasm associated with JAK2
mutations (V617F or exon 12) in almost all cases. The World Health Organization has …

Reactive oxygen species (ROS) have been implicated in a wide variety of disorders ranging
between traumatic, infectious, inflammatory, and malignant diseases. ROS are involved in …

Abstract Introduction Patients with Philadelphia-negative myeloproliferative neoplasms (Ph-
MPNs) are at increased risk of thromboembolic and hemorrhagic complications. The aim of …